JPWO2021141041A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021141041A5
JPWO2021141041A5 JP2021570066A JP2021570066A JPWO2021141041A5 JP WO2021141041 A5 JPWO2021141041 A5 JP WO2021141041A5 JP 2021570066 A JP2021570066 A JP 2021570066A JP 2021570066 A JP2021570066 A JP 2021570066A JP WO2021141041 A5 JPWO2021141041 A5 JP WO2021141041A5
Authority
JP
Japan
Prior art keywords
same
group
optionally substituted
alkyl
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021570066A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021141041A1 (cg-RX-API-DMAC7.html
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/000184 external-priority patent/WO2021141041A1/ja
Publication of JPWO2021141041A1 publication Critical patent/JPWO2021141041A1/ja
Publication of JPWO2021141041A5 publication Critical patent/JPWO2021141041A5/ja
Withdrawn legal-status Critical Current

Links

JP2021570066A 2020-01-07 2021-01-06 Withdrawn JPWO2021141041A1 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020001010 2020-01-07
JP2020094656 2020-05-29
PCT/JP2021/000184 WO2021141041A1 (ja) 2020-01-07 2021-01-06 タウオパチーの治療剤

Publications (2)

Publication Number Publication Date
JPWO2021141041A1 JPWO2021141041A1 (cg-RX-API-DMAC7.html) 2021-07-15
JPWO2021141041A5 true JPWO2021141041A5 (cg-RX-API-DMAC7.html) 2024-01-15

Family

ID=76788006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021570066A Withdrawn JPWO2021141041A1 (cg-RX-API-DMAC7.html) 2020-01-07 2021-01-06

Country Status (6)

Country Link
US (1) US20230109839A1 (cg-RX-API-DMAC7.html)
EP (1) EP4104861A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2021141041A1 (cg-RX-API-DMAC7.html)
CN (1) CN115397467A (cg-RX-API-DMAC7.html)
CA (1) CA3166986A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021141041A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12054486B2 (en) 2021-09-24 2024-08-06 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
GB2640329A (en) * 2024-04-09 2025-10-15 Imperial College Innovations Ltd Hedgehog acyltransferase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0216224D0 (en) 2002-07-12 2002-08-21 Glaxo Group Ltd Compounds
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
FR2889847B1 (fr) 2005-08-18 2007-10-05 Sanofi Aventis Sa Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique.
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
CN109112126B (zh) * 2010-06-23 2024-06-14 库尔纳公司 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
US20140073651A1 (en) 2011-02-22 2014-03-13 Actelion Pharmaceuticals Ltd. Benzamide derivatives as p2x7 receptor antagonists
CA2992406A1 (en) 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as irak-4 inhibitors
TW202500565A (zh) 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
CN118345115A (zh) * 2017-12-01 2024-07-16 编码治疗公司 工程化的dna结合蛋白
EP3828174A4 (en) * 2018-07-19 2022-08-17 Sumitomo Pharma Co., Ltd. PYRIDAZINONE DERIVATIVE

Similar Documents

Publication Publication Date Title
EP3630770B1 (en) Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
WO2019165073A1 (en) Shp2 phosphatase inhibitors and methods of use thereof
JP2021528446A5 (cg-RX-API-DMAC7.html)
CN111936486A (zh) 用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物
IL281188B2 (en) Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
RU2020112759A (ru) Гетероциклические соединения в качестве ингибиторов PAD
RU2018123825A (ru) Соединения и способы для модуляции киназ, и показания для этого
JP2001097889A (ja) Crfアンタゴニストおよび関連組成物の使用
JP2014528479A5 (cg-RX-API-DMAC7.html)
JP2020526549A5 (cg-RX-API-DMAC7.html)
CN105272930A (zh) 取代脲衍生物及其在药物中的应用
JP2016537384A5 (cg-RX-API-DMAC7.html)
RU2007107910A (ru) Гетероциклические соединения
EP3218376A1 (en) Bromodomain inhibitors and uses thereof
JP2004505964A5 (cg-RX-API-DMAC7.html)
JP2011507854A5 (cg-RX-API-DMAC7.html)
JP2011520832A5 (cg-RX-API-DMAC7.html)
RU2008110915A (ru) Новые диазаспироалканы и их применение для лечения заболеваний, опосредованных ccr8
EP2757884A1 (en) Pyrazolopyridyl compounds as aldosterone synthase inhibitors
JP2022527588A5 (cg-RX-API-DMAC7.html)
RU2010136057A (ru) (ДИГИДРО)ПИРРОЛО[2,1-a]ИЗОХИНОЛИНЫ
RU2008133588A (ru) ПРОИЗВОДНЫЕ 6-ФЕНИЛ-1Н-ИМИДАЗО[4,5-с]ПИРИДИН-4-КАРБОНИТРИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ КАТЕПСИНА К И S
RU2019126033A (ru) Бициклические амины в качестве новых ингибиторов jak-киназы
AU2015308522A1 (en) Products for the treatment and prevention of neurological disorders coursing with a cognition deficit or impairment, and of neurodegenerative diseases
RU2010148534A (ru) Производные имидазолидинона в качестве ингибиторов в 11b-hsd1